Close

ATP1B1

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The protein encoded by this gene belongs to the family of Na+/K+ and H+/K+ ATPases beta chain proteins, and to the subfamily of Na+/K+ -ATPases. Na+/K+ -ATPase is an integral membrane protein responsible for establishing and maintaining the electrochemical gradients of Na and K ions across the plasma membrane. These gradients are essential for osmoregulation, for sodium-coupled transport of a variety of organic and inorganic molecules, and for electrical excitability of nerve and muscle. This enzyme is composed of two subunits, a large catalytic subunit (alpha) and a smaller glycoprotein subunit (beta). The beta subunit regulates, through assembly of alpha/beta heterodimers, the number of sodium pumps transported to the plasma membrane. The glycoprotein subunit of Na+/K+ -ATPase is encoded by multiple genes. This gene encodes a beta 1 subunit. Alternatively spliced transcript variants encoding different isoforms have been described, but their biological validity is not known. [provided by RefSeq, Mar 2010]
  • CAR Vector Products

  • DMAb

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-CQ0037 Anti-ATP1B1 (464.8 (8A)) h(41BB-CD3ζ) CAR, pCDCAR1 Human, Rat, Pig, Cattle, Dog, Hamster, Rabbit, African clawed frog 464.8 (8A) Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ0038 Anti-ATP1B1 (M17-P5-F11) h(41BB-CD3ζ) CAR, pCDCAR1 Human, Mouse, Dog, Fruit fly, Pig, Rat, Sheep M17-P5-F11 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ3461 Anti-ATP1B1 (464.8 (8A)) h(CD28-CD3ζ) CAR, pCDCAR1 Human, Rat, Pig, Cattle, Dog, Hamster, Rabbit, African clawed frog 464.8 (8A) Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ3462 Anti-ATP1B1 (M17-P5-F11) h(CD28-CD3ζ) CAR, pCDCAR1 Human, Mouse, Dog, Fruit fly, Pig, Rat, Sheep M17-P5-F11 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ0022 Anti-ATP1B1 (CBWJN-0632) h(41BB-CD3ζ) CAR, pCDCAR1 CBWJN-0632 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ2314 Anti-ATP1B1 (CBWJN-0632) h(CD28-CD3ζ) CAR, pCDCAR1 CBWJN-0632 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY3283 Anti-ATP1B1 (XR6) h(41BB-CD3ζ) CAR, pCDCAR1 Avian XR6 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY3284 Anti-ATP1B1 (B4b4) h(41BB-CD3ζ) CAR, pCDCAR1 Avian B4b4 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY3421 Anti-ATP1B1 (XR6) h(CD28-CD3ζ) CAR, pCDCAR1 Avian XR6 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY3422 Anti-ATP1B1 (B4b4) h(CD28-CD3ζ) CAR, pCDCAR1 Avian B4b4 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.